BioSpace News Archive

Merck (NYSE: MRK) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to KEYTRUDA, Merck’s anti-PD-1 therapy, for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.

AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Second Quarter of Fiscal 2023 on Tuesday, May 2, 2023, prior to the opening of trading on the New York Stock Exchange.

Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today announced financial results for the year ended December 31, 2022, and recent business highlights.

The U.S. Food and Drug Administration (FDA) announced Wednesday that the agency has approved Naloxone Nasal Spray for over-the-counter use.

Galmed Pharmaceuticals Ltd. announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission.

Asklepios BioPharmaceutical, Inc. (AskBio) will present the preliminary results of a clinical Phase 1b study investigating the safety and efficacy of AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of mild to moderate Parkinson’s disease at the AD/PD™ 2023 Advances in Science & Therapy Conference taking place March 28–April 1, 2023.

Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences.

PaxMedica, Inc. provided a business update and reported financial results for the fourth quarter and year ended December 31, 2022.

ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration for Phase I clinical trial in China on March 29, 2023.

Avadel Pharmaceuticals plc announced the pricing of an underwritten public offering of 10,000,001 of its ordinary shares, nominal value $0.01 per share in the form of American Depositary Shares and of 4,705,882 Series B Non-Voting Convertible Preferred Shares, convertible into Ordinary Shares on a one-for-one basis.